Compare · COLL vs SCLX
COLL vs SCLX
Side-by-side comparison of Collegium Pharmaceutical Inc. (COLL) and Scilex Holding Company (SCLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. COLL focuses on Biotechnology: Pharmaceutical Preparations, while SCLX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- COLL is the larger of the two at $786.8M, about 64.8x SCLX ($12.1M).
- COLL has hit the wire 7 times in the past 4 weeks while SCLX has been quiet.
- COLL has more recent analyst coverage (23 ratings vs 6 for SCLX).
- Company
- Collegium Pharmaceutical Inc.
- Scilex Holding Company
- Price
- -
- -
- Market cap
- $786.8M
- $12.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 7
- 0
- Recent ratings
- 23
- 6
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Latest COLL
- Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.
- SEC Form SCHEDULE 13G filed by Collegium Pharmaceutical Inc.
- SEC Form 10-Q filed by Collegium Pharmaceutical Inc.
- Collegium Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by Collegium Pharmaceutical Inc.
- Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
- Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
- Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
- SEC Form 8-K filed by Collegium Pharmaceutical Inc.
Latest SCLX
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by Scilex Holding Company
- Large owner Scilex Holding Co disposed of $15,755,000 worth of shares (50,000,000 units at $0.32), decreasing direct ownership by 23% to 163,766,229 units (SEC Form 4)
- SEC Form 10-Q filed by Scilex Holding Company
- JP 3E Holdings, Inc. Appoints Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to Board of Directors
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Large owner Sclx Stock Acquisition Jv Llc disposed of 500,000 shares, decreasing direct ownership by 34% to 958,263 units (SEC Form 4)
- Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026